Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,741,321 papers from all fields of science
Search
Sign In
Create Free Account
Investigational New Drug Application
Known as:
Investigational New Drug (IND)
, Investigational New Drug Applications
An application that must be submitted to a regulatory agency (the FDA in the United States) before a drug can be studied in humans. This application…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Investigational New Drugs
legislation & jurisprudence
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Geron's quixotic fate
Christopher Scott
,
B. Huggett
Nature Biotechnology
2012
Corpus ID: 5579104
Why did Geron—corporate standard bearer for regenerative medicine—fail, whereas technology pioneers in other areas persist?
2009
2009
Expanded access to investigational drugs for treatment use. Final rule.
Federal register
2009
Corpus ID: 46447091
The Food and Drug Administration (FDA) is amending its regulations on access to investigational new drugs for the treatment of…
Expand
Review
2008
Review
2008
Human subject protection; foreign clinical studies not conducted under an investigational new drug application. Final rule.
Federal register
2008
Corpus ID: 37620684
The Food and Drug Administration (FDA) is amending its regulations on acceptance of foreign clinical studies not conducted under…
Expand
Review
2005
Review
2005
Vaccine INDs: review of clinical holds.
Daryll L Miller
,
J. Ross
Vaccine
2005
Corpus ID: 41676584
Review
2004
Review
2004
New drug approval process : accelerating global registrations
R. Guarino
2004
Corpus ID: 68376387
PARTIAL CONTENTS Regulatory Practices and Procedures of New Drug, Biologics and Device Development New Product Development Teams…
Expand
Review
1996
Review
1996
A NEW LOOK AT UNITED STATES DRUG DEVELOPMENT AND APPROVAL TIMES
J. DiMasi
American Journal of Therapeutics
1996
Corpus ID: 45396148
Clinical development and regulatory approval times for new chemical entities (NCEs) approved in the United States through 1995…
Expand
Review
1994
Review
1994
Regulatory considerations for oligonucleotide drugs: updated recommendations for pharmacology and toxicology studies.
L. Black
,
J. Farrelly
,
+5 authors
A. Jordan
Antisense Research and Development
1994
Corpus ID: 39581488
This article describes pharmacology and toxicity studies for oligonucleotide drugs that are recommended for inclusion in the…
Expand
1994
1994
Regulatory considerations on the role of general pharmacology studies in the development of therapeutic agents
A. Proakis
1994
Corpus ID: 58179396
In contrast to the well‐defined regulatory requirements for the conduct of animal toxicology studies, FDA regulations and…
Expand
1993
1993
Regulatory considerations for evaluating the pharmacology and toxicology of antisense drugs.
L. Black
,
J. Degeorge
,
J. Cavagnaro
,
A. Jordan
,
C. Ahn
Antisense Research and Development
1993
Corpus ID: 27541328
This article focuses on pharmacology and toxicology data that should be included in an Investigational New Drug Application (IND…
Expand
Review
1991
Review
1991
Polymer-modified proteins: preclinical development and regulatory strategies
P. C. Hoyle
1991
Corpus ID: 71209897
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE